We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Cost-Effectiveness of Media for Melioidosis Diagnosis Reviewed

By LabMedica International staff writers
Posted on 09 Aug 2019
Melioidosis is a frequently fatal disease caused by a soil bacterium called Burkholderia pseudomallei that is widespread in the rural tropics. More...
The yield of B. pseudomallei from sites with a normal flora is increased by culture using selective, differential media such as Ashdown’s agar and selective broth.

Because staff are often not familiar with B. pseudomallei and because it may be hidden if it is outgrown by other bacteria, special culture media can help laboratories diagnose the disease. However, this costs more money so it is not always done even in areas where the disease is known to be present.

A team of international scientists led by the University of Oxford (Oxford, England) reviewed the results of all cultures in the microbiology laboratories of a hospital in Laos and a Hospital for Children in Cambodia, in 2017. They identified patients with melioidosis who were only diagnosed as a result of culture of non-sterile sites and established the total number of such samples cultured using selective media and the associated costs in each laboratory.

The investigators then conducted a rudimentary cost-effectiveness analysis by determining the incremental cost-effectiveness ratio (ICER) per DALY averted and compared this against the 2017 GDP per capita in each country. In both laboratories, colonies suspected of being B. pseudomallei were screened by Gram stain, oxidase test and latex agglutination. Routine confirmation of identity was by API 20NE.

The team reported that overall, 29 patients in Laos and nine in Cambodia (20% and 16.9% of all culture-positive patients respectively) would not have been diagnosed without the use of selective media, the majority of whom (18 and eight respectively) were diagnosed by throat swab culture. The cost per additional patient detected by selective culture was approximately USD100 in Laos and USD39 in Cambodia. Despite the different patient populations (all ages in Laos versus only children in Cambodia) and testing strategies (all samples in Laos versus based on clinical suspicion in Cambodia), selective B. pseudomallei culture proved highly cost effective in both settings, with an ICER of ~USD170 and ~USD28 in Laos and Cambodia, respectively.

The authors concluded that in any patients with suspected melioidosis they recommend that, in addition to blood culture, a throat swab, or a good quality sputum sample if available, should be sent specifically for culture on Ashdown’s agar (ASH) and in Ashdown’s selective enrichment broth subcultured onto Ashdown’s agar only (SB), and a centrifuged deposit of urine should also be cultured on ASH. In areas of high melioidosis incidence, they also recommend the use of ASH and SB for any sputum and endotracheal aspirates received from patients with pneumonia. The study was published on July 15, 2019, in the journal PLOS Neglected Tropical Diseases.

Related Links:
University of Oxford


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.